However, analysts project potential upside of 92% in 2025, according to the Street-high estimate.  Investors should also note that Merck pays a dividend yielding 3.71%, more than twice the healthcare ...

Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics ( SMMT -2.71%). The drugmaker's shares are up by nearly 540%, thanks to excellent clinical ...

4Q23 results included charges related to the Daiichi Sankyo collaboration .

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

In addition, efti in combination with KEYTRUDA continues to be well-tolerated with no new ... treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer (1L NSCLC).

Summit Therapeutics has soared due to hopes around its cancer drug candidate, ivonescimab. It outperformed Keytruda in a phase 3 trial for treating advanced non-small cell lung cancer. Investors ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...

The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine ...